Fry Hannah's most recent trade in Protara Therapeutics Inc was a trade of 55,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Protara Therapeutics Inc | Hannah Fry | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Protara Therapeutics Inc | Hannah Fry | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 9,500 | 38,942 (0%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Hannah Fry | VP, Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. | 21 Jan 2025 | 2,130 | 27,312 (0%) | 0% | 4.8 | 10,139 | Common Stock |
| Protara Therapeutics Inc | Hannah Fry | VP, Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.14 per share. | 03 Jan 2025 | 394 | 29,442 (0%) | 0% | 6.1 | 2,419 | Common Stock |
| Protara Therapeutics Inc | Fry Hannah | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 46,000 | 46,000 | - | - | Stock Option (Right to Buy) | |
| Protara Therapeutics Inc | Hannah Fry | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 8,000 | 30,740 (0%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Fry Hannah | VP, Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.91 per share. | 19 Jan 2024 | 904 | 29,836 (0%) | 0% | 1.9 | 1,727 | Common Stock |
| Protara Therapeutics Inc | Fry Hannah | VP, Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 03 Jan 2024 | 324 | 22,740 (0%) | 0% | 2.2 | 703 | Common Stock |
| Protara Therapeutics Inc | Hannah Fry | VP, Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.56 per share. | 17 Jul 2023 | 10,075 | 23,064 (0%) | 0% | 2.6 | 25,792 | Common Stock |
| Protara Therapeutics Inc | Hannah Fry | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 35,400 | 35,400 | - | - | Stock Option (Right to Buy) | |
| Protara Therapeutics Inc | Hannah Fry | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 5,900 | 33,139 (0%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Hannah Fry | VP, Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.80 per share. | 03 Jan 2023 | 361 | 27,239 (0%) | 0% | 2.8 | 1,011 | Common Stock |
| Protara Therapeutics Inc | Hannah Fry | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2022 | 25,000 | 27,600 (0%) | 0% | 0 | Common Stock |